Skip to main content
. 2020 Mar 19;13(4):769–776. doi: 10.1111/cts.12763

Table 1.

Statistical analysis of mean change from baseline in QTcF

Time, hour

Mean change from baseline, msec

ddQTcF

Mean difference vs. placebo (90% CI), msec

ddQTcF

FTR

1,200 mg q.d. (A)

FTR

2,400 mg b.i.d. (B)

MOX

400 mg

(C)

Placebo

(D)

FTR

1,200 mg q.d.

(A–D)

FTR

2,400 mg b.i.d.

(B–D)

MOX

400 mg

(C–D)

0.5 –7.44 –6.04 –7.12 –7.54 0.10 (–1.98, 2.18) 1.50 (–0.63, 3.62) 0.42 (–1.73, 2.58)
1 –7.25 –6.15 –4.82 –7.76 0.51 (–1.57, 2.58) 1.61 (–0.51, 3.73) 2.95 (0.80, 5.10)
2 –6.78 –6.90 –1.93 –10.62 3.84 (1.75, 5.93) 3.72 (1.60, 5.84) 8.69 (6.57, 10.82)a
3 –7.54 –3.67 0.40 –10.03 2.49 (0.40, 4.57) 6.36 (4.23, 8.48) 10.43 (8.32, 12.54)b
4 –3.37 1.64 3.30 –7.03 3.66 (1.58, 5.75) 8.67 (6.55, 10.79) 10.33 (8.22, 12.44)c
5 –0.49 6.50 4.16 –4.67 4.18 (2.11, 6.26) 11.18 (9.05, 13.30) 8.83 (6.72, 10.94)
6 –4.52 0.18 –0.81 –8.78 4.27 (2.19, 6.34) 8.96 (6.84, 11.10) 7.98 (5.87, 10.09)
8 –6.87 –3.46 –0.74 –8.79 1.92 (–0.15, 3.40) 5.33 (3.21, 7.46) 8.05 (5.94, 10.17)
10 0.76 1.51 5.78 –3.18 3.94 (1.86, 6.01) 4.69 (2.57, 6.81) 8.96 (6.85, 11.07)
11.5 –5.31 –3.88 1.83 –6.92 1.61 (–0.48, 3.69) 3.04 (0.92, 5.17) 8.75 (6.64, 10.86)
14 –7.05 –1.65 0.60 –6.95 –0.10 (–2.18, 1.972) 5.30 (3.18, 7.43) 7.55 (5.44, 9.66)
15 –3.84 4.45 1.49 –4.15 0.30 (–1.78, 2.38) 8.60 (6.47, 10.73) 5.64 (3.52, 7.75)
16 –1.48 8.59 5.41 –1.52 0.04 (–2.04, 2.12) 10.10 (7.98, 12.23) 6.92 (4.81, 9.03)
22.25 –3.18 0.16 2.73 –3.46 0.29 (–1.79, 2.36) 3.63 (1.51, 5.75) 6.19 (4.08, 8.30)

CI, confidence interval; ddQTcF, difference vs. placebo for change from baseline in Fridericia‐corrected QT interval; FTR, fostemsavir; MOX, moxifloxacin; QTcF, Fridericia‐corrected QT interval.

Multiplicity‐adjusted 90% CI for MOX: a(6.57; 10.82); b(7.70; 13.16); c(7.81; 12.84).